3.39  -0.43 (-11.26%)		03-02 16:00
Open: 3.52 High: 3.82 Volume: 325,952		Pre. Close: 3.82 Low: 3.22 Market Cap: 17(M)

Short term
Mid term
Targets	6-month :	37.52	1-year :	58.39
Resists	First :	32.12	Second :	50
Pivot price	0
Supports	First :	3.21	Second :	2.67
MAs	MA(5) :	4.98	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	20.66	Low :	3.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AIDX ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	3.84 - 3.88	3.88 - 3.9
Low:	3.15 - 3.19	3.19 - 3.22
Close:	3.34 - 3.41	3.41 - 3.45

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

Sat, 28 Feb 2026
20/20 Biolabs, Inc. Common Stock (AIDX) AI-Powered Stock Analysis - Meyka

Sat, 28 Feb 2026
AIDX News Today: Stay Updated with the Latest 20/20 Biolabs, Inc. Common Stock News in Real Time - Meyka

Sat, 28 Feb 2026
Why Is 20/20 Biolabs, Inc. Common Stock (AIDX) Stock Up Today? - Meyka

Sat, 28 Feb 2026
20/20 Biolabs, Inc. Common Stock (AIDX) Fundamental Analysis - Meyka

Tue, 24 Feb 2026
Total common shares outstanding of 20/20 Biolabs, Inc. – BOATS:AIDX - TradingView

Tue, 24 Feb 2026
20/20 Biolabs, Inc. Statistics – NASDAQ:AIDX - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0.1 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-0.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-159.4 %
Operating Margin	-191.5 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	15.8 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-2 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-4.99
PEG Ratio	0
Price to Book value	339
Price to Sales	0
Price to Cash Flow	-0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.